NasdaqGM:ZYNE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$180.7m

Last Updated

2021/07/24 23:38 UTC

Data Sources

Company Financials +

Executive Summary

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Zynerba Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZYNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ZYNE's weekly volatility has decreased from 15% to 9% over the past year.


Market Performance


7 Day Return

-1.3%

ZYNE

2.5%

US Pharmaceuticals

2.0%

US Market


1 Year Return

26.3%

ZYNE

17.7%

US Pharmaceuticals

39.1%

US Market

Return vs Industry: ZYNE exceeded the US Pharmaceuticals industry which returned 17.7% over the past year.

Return vs Market: ZYNE underperformed the US Market which returned 39.1% over the past year.


Shareholder returns

ZYNEIndustryMarket
7 Day-1.3%2.5%2.0%
30 Day-21.8%3.6%1.6%
90 Day7.1%7.2%3.5%
1 Year26.3%26.3%22.6%17.7%41.3%39.1%
3 Year-36.0%-36.0%35.5%24.2%64.0%53.8%
5 Year-49.0%-49.0%46.6%27.6%123.9%99.0%

Long-Term Price Volatility Vs. Market

How volatile is Zynerba Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zynerba Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ZYNE ($4.51) is trading below our estimate of fair value ($12.98)

Significantly Below Fair Value: ZYNE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ZYNE is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ZYNE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZYNE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZYNE is good value based on its PB Ratio (1.9x) compared to the US Pharmaceuticals industry average (3x).


Future Growth

How is Zynerba Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

40.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ZYNE's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ZYNE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYNE is forecast to be unprofitable in 3 years.


Past Performance

How has Zynerba Pharmaceuticals performed over the past 5 years?

-16.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZYNE is currently unprofitable.

Growing Profit Margin: ZYNE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZYNE is unprofitable, and losses have increased over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare ZYNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZYNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).


Return on Equity

High ROE: ZYNE has a negative Return on Equity (-49.06%), as it is currently unprofitable.


Financial Health

How is Zynerba Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ZYNE's short term assets ($107.2M) exceed its short term liabilities ($12.6M).

Long Term Liabilities: ZYNE's short term assets ($107.2M) exceed its long term liabilities ($525.1K).


Debt to Equity History and Analysis

Debt Level: ZYNE is debt free.

Reducing Debt: ZYNE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZYNE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ZYNE has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 22.9% each year.


Dividend

What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZYNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZYNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYNE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZYNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Armando Anido (63 yo)

6.75yrs

Tenure

US$1,482,749

Compensation

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has e...


CEO Compensation Analysis

Compensation vs Market: Armando's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD1.11M).

Compensation vs Earnings: Armando's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ZYNE's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: ZYNE's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.7%.


Top Shareholders

Company Information

Zynerba Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zynerba Pharmaceuticals, Inc.
  • Ticker: ZYNE
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$180.696m
  • Shares outstanding: 40.07m
  • Website: https://zynerba.com

Number of Employees


Location

  • Zynerba Pharmaceuticals, Inc.
  • 80 West Lancaster Avenue
  • Suite 300
  • Devon
  • Pennsylvania
  • 19333
  • United States

Listings


Biography

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/24 23:38
End of Day Share Price2021/07/23 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.